Immune cells reprogrammed to hunt prostate cancer in early trial
NCT ID NCT01140373
First seen Dec 09, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-phase study tests whether a patient's own immune cells can be genetically modified to recognize and attack prostate cancer cells. Thirteen men with advanced prostate cancer that no longer responds to hormone therapy will receive their own altered T cells. The main goal is to check safety and find the right dose, while also looking for any signs that the treatment shrinks tumors or slows the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.